secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eledon Pharmaceuticals, Inc. (ELDN)
CIK:        0001404281
Form:       8-K
Filed at:   2023-03-30T23:59:59+00:00
Accession:  0000950170-23-010924
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eledon reports Q4 2022 net loss of $58.4M, including $48.6M goodwill impairment; refocuses on kidney transplant
--------------------------------------------------------------------------------

- Q4 2022 net loss $58.4M ($4.09/share) vs $8.8M ($0.59) in Q4 2021; full-year net loss $88.0M ($6.16) vs $34.5M ($2.33).
- Cash and equivalents $56.4M at Dec 31, 2022; expected to fund operations into Q1 2024.
- Phase 1b kidney transplant trial dosed fourth patient; data on first three to be presented at WCN March 31, 2023.
- Deprioritized IgAN program and discontinued islet cell trial; collaboration with eGenesis for xenotransplantation.
- Subject to financing, Phase 2 BESTOW trial of tegoprubart in kidney transplant expected to initiate mid-2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1404281/000095017023010924/0000950170-23-010924-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1404281/000095017023010924/eldn-20230330.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-010924

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer